Fluoride: mode of action.
Caverzasio
J
J
WHO Collaborating Center for Osteoporosis and Bone Diseases, Department of Internal Medicine, University Hospital, Geneva, Switzerland. caverzas@cmu.unige.ch
Palmer
G
G
Bonjour
J P
JP
D000818:Animals; D001846:Bone Development / Q000187:drug effects*; D001862:Bone Resorption / Q000188:drug therapy*; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism / Q000502:physiology; D002460:Cell Line; D005459:Fluorides / Q000008:administration & dosage / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000378:metabolism / Q000502:physiology; D006801:Humans; D019950:Mitogen-Activated Protein Kinase 1; D010006:Osteoblasts / Q000187:drug effects* / Q000201:enzymology; D017027:Protein Tyrosine Phosphatases / Q000378:metabolism / Q000502:physiology
D017871:Calcium-Calmodulin-Dependent Protein Kinases; D019950:Mitogen-Activated Protein Kinase 1; D017027:Protein Tyrosine Phosphatases; D019204:GTP-Binding Proteins; D005459:Fluorides